Neuropharmacology of verbal perseveration

Seminars in Speech and Language

Volumn 25, Issue 4, 2004, Pages 309-321

  McNamara, Patrick ^a   Albert, Martin L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine; Catecholamines; Dopamine; Executive function; Inhibition; Norepinephrine; Perseveration; Prefrontal cortex

Indexed keywords

ACETYLCHOLINE; AMPHETAMINE DERIVATIVE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEMELANE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CLONIDINE; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; METHYLPHENIDATE; NORADRENALIN; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; PIRACETAM; RISPERIDONE; SCOPOLAMINE;

ALZHEIMER DISEASE; CATECHOLAMINERGIC SYSTEM; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMMUNICATION DISORDER; CORTICAL SENSORY APHASIA; DEMENTIA; EVIDENCE BASED MEDICINE; FOREBRAIN; HUMAN; MEMORY; NEUROANATOMY; NEUROMODULATION; NEUROPHARMACOLOGY; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; PERSEVERATION; POSTSYNAPTIC INHIBITION; PREFRONTAL CORTEX; PRESYNAPTIC INHIBITION; PRIMARY PROGRESSIVE APHASIA; RECALL; REVIEW; SCHIZOPHRENIA; SELECTIVE ATTENTION; SPEECH AND LANGUAGE; TEMPORAL LOBE; VERBAL COMMUNICATION;

ACETYLCHOLINE; ADRENERGIC ALPHA-AGONISTS; CATECHOLAMINES; CHOLINERGIC AGENTS; COMMUNICATION DISORDERS; DOPAMINE; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PREFRONTAL CORTEX; PROSENCEPHALON; SPEECH DISORDERS; TEMPORAL LOBE; VERBAL BEHAVIOR;

EID: 10944260239     PISSN: 07340478     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-837244     Document Type: Review

References (108)

1. Albert M, Sandson J. Perseveration in aphasia. Cortex 1986;22:103-115
2. Yamdori A. Verbal perseveration in aphasia. Neuropsychologia 1981;18:591-594
3. Santo-Pietro MJ, Rigrodsky S. The effects of temporal and semantic conditions on the occurrence of the error response of perseveration in adult aphasics. J Speech Hear Res 1982;25:184-192
4. Emery P, Helm-Estabrooks N. The role of perseveration in aphasic confrontation naming performance. Proceedings of Clinical Aphasiology 1989;18:64-83
5. Bayles KA, Tomoeda CK, Kaszniak AW, Stern LZ, Eagans KK. Verbal perseveration of dementia patients. Brain Lang 1985;25:102-116
6. Barr WB, Bilder RM, Goldberg E, Kaplan E, Mukherjee S. The neuropsychology of schizophrenic speech. J Commun Disord 1989;22:327-349
7. DeLisi LE. Speech disorder in schizophrenia: review of the literature and exploration of its relation to the uniquely human capacity of language. Schizophr Bull 2001;27:481-496
8. Bayles KA, Trosset MW, Tomoeda CK, Montgomery EB, Wilson J. Generative naming in Parkinson disease patients. J Clin Neuropsychol 1993;15:547-562
9. Benke T, Hohenstein C, Poewe W, Butterworth B. Repetitive speech phenomena in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69: 319-325
10. Butters M, Goldstein G, Allen D, Shemansky W. Neuropsychological similarities and differences among Huntington's disease, multiple sclerosis, and cortical dementia. Arch Clin Neuropsychol 1998;13:721-735
11. Ridley RM. The psychology of perseverative and stereotyped behavior. Prog Neurobiol 1994;44: 221-231
12. Hotz G, Helm-Estabrooks N. Perseveration. Part II. A study of perseveration in closed-head injury. Brain Inj 1995;9:160-171
13. Lombardi W, Andreason P, Sirocco K, et al. Wisconsin Card Sorting Test performance following head injury: Dorsolateral fronto-striatal circuit activity predicts perseveration. J Clin Exp Neuropsychol 1999;21:2-16
14. Sayles DG. Cortical excitability, perseveration and stuttering. J Speech Hear Res 1971;14:462-475
15. Aman MG. Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Ment Retard Dev Disabil Res Rev 1999;5:279-289
16. Branford D, Bhaumik S, Naik B. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 1998;42:301-306
17. Davis R, Nolen-Hoeksema S. Cognitive inflexibility among ruminators and nonruminators. Cognit Ther Res 2000;24:699-711
18. Fibiger HC. The organization and some projections of cholinergic neurons of the mammalian forebrain. Brain Res 1982;257:327-388
19. Semba K, Fibiger HC. Organization of central cholinergic systems. Prog Brain Res 1989;79: 37-63
20. Mesulam M-M. Central cholinergic pathways: neuroanatomy and some behavioral implications. In: Anoli M, Reader TA, Dykes RW, Gloor P, eds. Neurotransmitters and Cortical Functions. New York: Plenum; 1988:237-260
21. Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol 1997; 48:649-684
22. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002;68:209-245
23. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976;99:459-496
24. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-1459
25. Foote S, Morrison J. Extrathalamic modulation of cortical function. Annu Rev Neurosci 1987;10: 67-95
26. Amaducci L, Sorbi S, Albanese A, Gainotti G. Choline acetyltranserferase (ChAT) activity differs in right and left human temporal lobes. Neurology 1981;31:799-805
27. Glick S, Ross D, Hough L. Lateral asymmetry of neurotransmitters in human brain. Brain Res 1982;234:53-63
28. Hutsler JJ, Gazzaniga MS. Acetylcholinesterase staining in human auditory and language cortices: regional variation of structural features. Cereb Cortex 1996;6:260-270
29. Goldman-Rakic P. Circuitry of primate prefrontal cortex and regulation of behavior by representational memory. In: Mountcastle V, Plum F, eds. Higher Cortical Function, Handbook of Physiology. Bethesda: MD: American Physiological Society; 1987:373-417
30. Le Moal M, Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 1991;71:155-234
31. Lewis DA. The catecholaminergic innervation of primate prefrontal cortex. J Neural Transm Suppl 1992;36:179-200
32. Tzschentke TM. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 2001;63:241-320
33. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67: 53-83
34. Oke A, Keller I, Mefford I, Adams R. Lateralization of norepinephrine in human thalamus. Science 1978;200:1411-1413
35. Berridge CW, Espana RA, Stalnaker TA. Stress and coping: asymmetry of dopamine efferents within the prefrontal cortex. In: Hugdahl K, Davidson RJ, eds. The Asymmetrical Brain. Cambridge, MA: The MIT Press; 2003:69-104
36. Pizzagalli D, Shackman AJ, Davidson RJ. The functional neuroimaging of human emotion: asymmetric contributions of cortical and subcortical circuitry. In: Hugdahl K, Davidson RJ, eds. The Asymmetrical Brain. Cambridge, MA: The MIT Press; 2003:511-532
37. Coull JT. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog Neurobiol 1998;55:343-361
38. Arnsten AFT. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci 1998;2:436-447
39. Arnsten AFT, Goldman-Rakic PS. Alpha adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged non-human primates. Science 1985;230:1273-1276
40. Sara SJ, Herve-Minville A. Inhibitory influence of frontal cortex on locus coeruleus. Proc Natl Acad Sci USA 1995;92:6032-6036
41. Berridge CW, Arnsten A, Foote S. Noradrenergic modulation of cognitive function. Psychol Med 1993;23:557-564 (editorial)
42. D'Esposito M, Albert ML. Pharmacology of memory. In: Memoire et Vieillissement. Paris: Maloine Editeur; 1991:247-252
43. Levin ED, Decker MW, Butcher LL, eds. Neurotransmitter Interactions and Cognitive Function. Boston: Birkhauser; 1992
44. Terry AV, Jackson WJ, Buccafusco JJ. Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cereb Cortex 1993;3: 304-312
45. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999; 45:1-16
46. Sandson J, Albert M. Perseveration in behavioral neurology. Neurology 1987;37:1736-1741
47. Morton JB, Munakata Y. Active versus latent representations: a neural network model of perseveration, dissociation and decalage. Dev Psychobiol 2002;40:255-265
48. Cohen L, Dehaene S. Competition between past and present: assessment and interpretation of verbal perseverations. Brain 1998;121:1641-1659
49. Gotts SJ, della Rocchetta AI, Cipolotti L. Mechanisms underlying perseveration in aphasia: evidence from a single case study. Neuropsychologia 2002;40:1930-1947
50. Brozoski T, Brown R, Rosvold H, Goldman P. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979;205:929-931
51. Watanabe M, Kodama T, Hikosaka K. Increase in extracellular dopamine in the primate prefrontal cortex during a working memory task. J Neurophysiol 1997;78:2795-2798
52. Gotham A, Brown R, Marsden C. "Frontal" cognitive functions in patients with Parkinson's disease "on" and "off" levodopa. Brain 1988;111: 299-321
53. Cools A, Berger H, Buytenhuijs E, Horstink M, Van Spaendonck K. Manifestations of switching disorders in animals and man with dopamine deficits in A10 and/or A9 circuitries. In: Wolters E, Scheltens P, eds. Mental Dysfunction in Parkinson's Disease. Dordrecht, The Netherlands: ICG; 1995:49-68
54. Lange KW, Paul GM, Naumann M, Gesell W. Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J Neural Transm Suppl 1995;46:423-432
55. Taylor A, Saint-Cyr J. The neuropsychology of Parkinson's disease. Brain Cogn 1995;28:281-296
56. Downes J, Sharp H, Costall B, Sagar H, Howe J. Alternating fluency in Parkinson's disease: an evaluation of the attentional control theory of cognitive impairment. Brain 1993;116:887-902
57. Lange KW, Robbins TW, Marsden CD, et al. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992;107:394-404
58. Callaway E, Halliday R, Naylor H. Cholinergic activity and constraints on information processing. Biol Psychiatry 1992;33:1-22
59. Meador KJ. An overview of neurotransmitters in cognitive function. In: Pharmacology of Cognition. Half-day course presented at the 49th Annual Meeting of the American Academy of Neurology Boston, MA; April 15-22, 1997
60. Rusted JM, Warburton DM. Cognitive models and cholinergic drugs. Neuropsychobiology 1989; 21:31-36
61. Arnsten AFT, Steere JC, Hunt RD. The contribution of alpha-2 noradrenergic mechanisms to prefrontal cortical cognitive function. Arch Gen Psychiatry 1996;53:448-455
62. Stern Y, Mayeux R, Cote L. Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism. Arch Neurol 1984;41:1086-1089
63. Mayeux R, Stern Y, Sano M, Cote L, Williams JBW. Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology 1987;37:1130-1134
64. Riekkinen M, Kejonen K, Jakala P, Soininen H, Riekkinen P Jr. Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease. Eur J Neurosci 1998;10:1429-1435
65. Kuiper MA, Wolters EC. CSF biochemistry in Parkinson's disease patients with mental dysfunction. In: Wolters E, Scheltens P, eds. Mental Dysfunction in Parkinson's Disease. Dordrecht, The Netherlands: ICG; 1995:163-176
66. McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999;6(Suppl 12):24-30
67. Green M, Marshall B, Wirshing W, et al. Does risperidone improve verbal working memory in treatment resistant schizophrenia? Am J Psychiatry 1997;154:799-804
68. McGurk S, Green M, Wirshing W, et al. The effects of risperidone vs. haloperidol in treatment-resistant schizophrenia: The trail-making test. CNS Spectr 1997;2:60-64
69. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725
70. Hoff A, Faustman W, Wieneke M, et al. The effect of clozapine on symptom reduction, neurocognitive function and clinical management in treatment refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996;15: 361-369
71. Murphy B, Arnsten AVF, Goldman-Rakic PS, Roth RH. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 1996;93:1325-1329
72. Kulisevsky J, Avial A, Barbanoj M, et al. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996;119:2121-2132
73. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong JT. Alzheimer's disease: evidence for a selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126
74. Bartus RT, Dean RL, Flicker C. Cholinergic psychopharmacology: an integration of human and animal research on memory. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987:219-232
75. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259
76. Farlow MR, Evans RM. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 1998;51(Suppl 1):S36-S44
77. DeKosky ST. Treatment of cognitive impairments in Alzheimer's disease. In: Pharmacology of Cognition. Education program syllabus presented at the 51st Annual Meeting of the American Academy of Neurology. Toronto, Ontario, Canada; April 17-24, 1999:2PC.005-1-2PC:005-13
78. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529
79. Knapp M, Knopman D, Solomon P, et al. A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991
80. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145
81. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999;318:633-640
82. Drachman DA, Leavitt J. Human memory and the cholinergic system. Arch Neurol 1974;30: 113-121
83. Thal LJ, Fuld PA, Masur OM, et al. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 1983;13:491-496
84. Fuld P, Katzman R, Davies P. Intrusions as a sign of Alzheimer dementia: chemical and pathological verification. Ann Neurol 1982;11:155-159
85. Tanaka Y, Minernatsu K, Hirano T, et al. Effects of COP-choline on dynamic changes in LCBF and cognitive function in demented subjects-An H2150-PET study [In Japanese with English abstract]. Clin Neurol 1994;34:877-881
86. Tanaka Y, Miyazaki M, Albert ML. Effect of increased cholinergic activity on naming in aphasia. Lancet 1997;350:116-117
87. Willmes K, Huber W, Poeck K, et al. Die Wirkung von Piracetam bei der logopadischen Intensivthepapie von chronish aphasischen Patienten. In: VonHelmchen, ed. Sonderd ruck ans Wirlumgen und WirksarnIeit von Nootropika. Berlin: Springer-Verlag; 1988:177-187
88. Aarsland O, Larsen JP, Reinvang I, et al. Effects of cholinergic blockade on language in healthy young women: implications for the cholinergic hypothesis in dementia of the Alzheimer's type. Brain 1994;117:1377-1384
89. Dubois B, Bernard P, Lhermitte F, et al. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 1990;28:117-121
90. Imamura T, Takanashi M, Hattori N, et al. Bromocriptine treatment for perseveration in demented patients. Alzheimer Dis Assoc Disord 1998;12:109-113
91. Buckingham HW, Christman SS. Phonemic carryover perseveration: word blends. Semin Speech Lang 2004;25:363-374
92. Leanderson R, Meyerson B, Persson A. Effect of L-Dopa on speech in Parkinsonism: an EMG study of labial articulatory function. J Neurol Neurosurg Psychiatry 1971;34:679-681
93. Nakano K, Zubick H, Tyler H. Speech defects of parkinsonian patients: effects of levodopa therapy on speech intelligibility. Neurology 1973;23:865-870
94. Quaglieri C, Celesia G. Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients. Eur J Neurol 1977;15:34-39
95. Wolfe V, Garvin J, Bacon M, Waldrop W. Speech changes in Parkinson's disease during treatment with L-dopa. J Commun Disord 1975;8:271-279
96. Critchley E. Speech disorders of Parkinsonism: a review. J Neurol Neurosurg Psychiatry 1981;44: 751-758
97. Cahill L, Murdoch B, Theodoros D, et al. Effect of oral levodopa treatment on articulatory function in Parkinson's disease. Motor Control 1998;2: 161-172
98. Goberman AM, Coelho C. Acoustic analysis of Parkinsonian speech. I: Speech characteristics and L-Dopa therapy. NeuroRehabilitation 2002;17: 237-246
99. Poluha P, Teulings H, Brookshire R. Handwriting and speech changes across the levadopa cycle in Parkinson's disease. Acta Psychol (Amst) 1998;100:71-84
100. Louis ED, Winfield L, Fahn S, Ford B. Speech dysfluency exacerbated by levodopa in Parkinson's disease. Mov Disord 1991;16:562-565
101. Benson DF. Presentation 10. In: Benton AL, ed. Behavioral Changes in Cerebrovascular Disease. New York: Harper and Row; 1970:77
102. McNeil MR, Small SL, Masterson RJ, Fossett T. Behavioral and pharmacological treatment of lexical-semantic deficits in case of primary progressive aphasia. Am J Speech Lang Pathol 1995; 4:76-87
103. Walker-Batson D. Pharmacotherapy in the treatment of aphasia. In: Goldstein LB, ed. Restorative Neurology: Advances in Pharmacotherapy for Recovery After Stroke. Armonk, NY: Futura Publishing; 1998:257-270
104. Albert ML, Bachman D, Morgan A, Helm-Estabrooks N. Pharmacotherapy for aphasia. Neurology 1988;38:877-879
105. Gupta SR, Mlcoch AG. Bromocriptine treatment of nonfluent aphasia. Arch Phys Med Rehabil 1992;73:373-376
106. Sabe L, Salvarezza F, Garcia Cuerva A, Leiguarda R, Starkstein S. A randomized double-blind placebo controlled study of bromocriptine in non-fluent aphasia. Neurology 1995;45:2272-2274
107. Bragoni M, Altieri M, Di Piero V, et al. Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke. Neurol Sci 2000;21: 19-22
108. Gupta SR, Mlcoch AJ, Scolaro C, Moritz T. Bromocriptine treatment of nonfluent aphasia. Neurology 1995;45:2170-2173